Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine
Who is this study for? Patients with tardive dyskinesia
What treatments are being studied? Valbenazine
Status: Withdrawn
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This will be an Investigator-initiated pilot study in which participants will be assessed with various scales to measure demoralization, anxiety, depression, and subjective incompetence at baseline and every two weeks after treatment with Valbenazine for a total of 6 weeks. Improvement in TD will be assessed as well and correlated with reduction in demoralization.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 26
Maximum Age: 84
Healthy Volunteers: f
View:
• Age: 26-84
• Sex: Both males and females will be included
• Diagnosis of dopamine receptor-blocker induced tardive dyskinesia according to the DSM-5 criteria: involuntary athetoid or choreiform movements lasting at least a few weeks, developing in association with the use of a neuroleptic medication for at least a few months, and persisting beyond 4-8 weeks
Locations
United States
Connecticut
Yale Church Street Research Unit.
New Haven
Time Frame
Start Date: 2024-10-18
Completion Date: 2025-10-18
Treatments
Experimental: Valbenazine
All participants will be treated with Valbenazine for 6 weeks.
Related Therapeutic Areas
Sponsors
Collaborators: Neurocrine Biosciences
Leads: Yale University